|
|
|
|
|
|
Adocia specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases.
Sales break down by revenue type into public subsidies and financing (94.9%) and revenues from research contracts and licenses (5.1%).
At the end of 2011, the group had a portfolio of 4 products in clinical development (including two in phase 3; PDGF-BB, for treating diabetic foot ulcers, and HinsBet, quick-acting human insulin for treating diabetes).
|
|
| Surperformance© rating of ADOCIA | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
- |
- |
- |
| Investor Rating |
- |
- |
- |
| Growth (Revenue) |
- |
- |
- |
| Valuation |
- |
- |
- |
| Finances |
- |
- |
- |
| Profitability |
- |
- |
- |
| Earnings quality |
- |
- |
- |
| Business Predictability |
- |
- |
- |
| PER |
- |
- |
- |
| Potential |
- |
- |
- |
| Yield |
- |
- |
- |
| Consensus |
- |
- |
- |
| 7 days EPS revision |
- |
- |
- |
| 4 months EPS revision |
- |
- |
- |
| 1 year EPS revision |
- |
- |
- |
| 4 months Revenue revision |
- |
- |
- |
| 1 year Revenue revision |
- |
- |
- |
| |
|
|
|
|
Data source :
© 2013 Thomson Reuters |
|
Ratings :
© 2013 Surperformance |
|
|
|
|
|
| - Financial investors |
59,40% |
| - Family Soula |
34,80% |
| - Société Hospitalière d' Assurances Mutuelles |
5,29% |
|
|
|
|
- Chairman and Chief Executive Officer :
Gérard Soula |
- Investor Relations :
Valérie Danaguezian |
- Chief Financial Officer :
Valérie Danaguezian |
|
|
| Company contact information |
|
115 avenue Lacassagne
69003 Lyon
France
Phone : +33 (0)4 72 610 610
Fax : +33 (0)4 72 36 39 67
Internet : http://www.adocia.com
|
|
|
|
- PEA / SRD eligible : NO / NO - NYSE Euronext Paris - Compartiment C - CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC Small |
|
|
|
|
| - ISIN Code : |
FR0011184241 |
| - Bloomberg Code : |
ADOC:FP |
| - Reuters Code : |
ADOC.PA |
| - Datastream Code : |
|
|
Financial data source :
© 2013 Cofisem |
|
|
